| Scott B Hutson, MD | |
|
1017 S 2nd Ave, Suite 1, Walla Walla, WA 99362-4116 | |
| (509) 525-4900 | |
| (509) 522-3886 |
| Full Name | Scott B Hutson |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 1017 S 2nd Ave, Walla Walla, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871540955 | NPI | - | NPPES |
| 1021011 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD00019935 (Washington) | Primary |
| Entity Name | Prosser Public Hospital District Of Benton County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897681 PECOS PAC ID: 6709787872 Enrollment ID: O20040120000974 |
News Archive
Since its establishment, National Health Center Week has celebrated the work of community health centers that provide health services to the working poor, the uninsured, the medically underserved, and many high risk and vulnerable populations. This year's National Health Center Week takes place from August 9 – 15.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.
Canadian researchers followed their intuition that a drug initially intended for heart failure could be effective in treating cancer. Those efforts have borne fruit, as demonstrated by their work published in the Journal of Experimental and Clinical Cancer Research.
› Verified 5 days ago
| Entity Name | Prosser Public Hospital District Of Benton County |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897681 PECOS PAC ID: 6709787872 Enrollment ID: O20060317000302 |
News Archive
Since its establishment, National Health Center Week has celebrated the work of community health centers that provide health services to the working poor, the uninsured, the medically underserved, and many high risk and vulnerable populations. This year's National Health Center Week takes place from August 9 – 15.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.
Canadian researchers followed their intuition that a drug initially intended for heart failure could be effective in treating cancer. Those efforts have borne fruit, as demonstrated by their work published in the Journal of Experimental and Clinical Cancer Research.
› Verified 5 days ago
| Entity Name | Ghch Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326217670 PECOS PAC ID: 7416011184 Enrollment ID: O20090123000367 |
News Archive
Since its establishment, National Health Center Week has celebrated the work of community health centers that provide health services to the working poor, the uninsured, the medically underserved, and many high risk and vulnerable populations. This year's National Health Center Week takes place from August 9 – 15.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.
Canadian researchers followed their intuition that a drug initially intended for heart failure could be effective in treating cancer. Those efforts have borne fruit, as demonstrated by their work published in the Journal of Experimental and Clinical Cancer Research.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott B Hutson, MD Po Box 1398, Walla Walla, WA 99362-0309 Ph: (509) 525-4900 | Scott B Hutson, MD 1017 S 2nd Ave, Suite 1, Walla Walla, WA 99362-4116 Ph: (509) 525-4900 |
News Archive
Since its establishment, National Health Center Week has celebrated the work of community health centers that provide health services to the working poor, the uninsured, the medically underserved, and many high risk and vulnerable populations. This year's National Health Center Week takes place from August 9 – 15.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.
Canadian researchers followed their intuition that a drug initially intended for heart failure could be effective in treating cancer. Those efforts have borne fruit, as demonstrated by their work published in the Journal of Experimental and Clinical Cancer Research.
› Verified 5 days ago
Dr. Erik C Gryler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 W Tietan St, Walla Walla, WA 99362 Phone: 509-525-3720 Fax: 509-522-1573 | |
Dr. Richard Lyle Henderson, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 380 Chase Ave, Orthopedics, Walla Walla, WA 99362 Phone: 509-522-5820 Fax: 509-522-5570 | |
Mr. Michael Wade Gillespie, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 Brookside Drive, Walla Walla, WA 99362 Phone: 509-525-1890 | |
Kirk Ellsworth Willard, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 380 Chase Ave, Orthopaedics, Walla Walla, WA 99362 Phone: 509-522-5820 Fax: 509-522-5570 | |
Michael James Wilwand, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 West Tietan Street, Walla Walla, WA 99362 Phone: 509-525-3720 Fax: 509-522-1592 |